Industry

U.S. Healthcare Staffing Market to Reach $34.7 Billion by 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “U.S. Healthcare Staffing Market Size, Share & Trends Analysis Report by Type (Travel Nurse Staffing, Per Diem Nurse Staffing, Locum Tenens Staffing, Allied Healthcare Staffing), and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. healthcare staffing market size is expected to reach USD 34.7 billion by 2030, exhibiting a … [Read more…]

Fujifilm and Qure.ai Join Hands With IHVN to Accelerate TB Screening in Rural Nigerian Communities

– Fujifilm’s Xair ultra-portable handheld, battery powered X-ray machine will be deployed with Qure.ai’s AI-enabled Chest X-ray solution to screen presumptive TB cases – The partnership is aimed at augmenting active screening for TB in hotspots with the support of USAID and the Lagos State TB program. LAGOS, Nigeria–(BUSINESS WIRE)–#AI–The Institute of Human Virology in … [Read more…]

InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Marginal Zone Lymphoma in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a supplemental New Drug Application (sNDA) for Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of patients with relapsed … [Read more…]

Disclosure of data on Agaricus blazei mushroom, KA21’s immunity-enhancing mechanism, immunological enhancement effect confirmed by human clinical trials, and candida and other types of fungal infection, Toei Shinyaku

TOKYO–(BUSINESS WIRE)–On its website www.toeishinyaku.jp, Toei Shinyaku has disclosed data concerning the mechanism by which Agaricus blazei KA21 enhances immunity, its immunological enhancement effect as confirmed by human clinical trials, and candida and other types of fungal infection. Agaricus blazei KA21 product has been sold in the Japanese market as a supplement for the immune … [Read more…]

Disclosure of data on effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair in human clinical trials and promotion of hair growth in mice, Toei Shinyaku

TOKYO–(BUSINESS WIRE)–On its website www.toeishinyaku.jp, Toei Shinyaku has disclosed data from human clinical trials concerning the effects of Agaricus blazei mushroom, KA21 strain for improvement of hair loss & gray hair, as well as its effects for promotion of hair growth in mice. Agaricus blazei mushroom, KA21 strain is being sold as a supplement within … [Read more…]

Announcement of Agaricus blazei mushroom, KA21 strain’s Ability to Improve QOL of Athletes at Annual Meeting, Toei Shinyaku

Athlete performance, overall condition, quality of sleep, sense of fatigue, mental condition, concentration ability, muscle condition, stamina, and resilience. TOKYO–(BUSINESS WIRE)–Toei Shinyaku gave an academic presentation regarding Agaricus blazei KA21 strain’s ability to improve QOL of athletes at the 22nd Annual Meeting of the Japanese Society of Anti-Aging Medicine. Human clinical trials confirmed the effects … [Read more…]

ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer

Based on DESTINY-Lung02 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reported a confirmed objective response rate of 57.7% in patients with HER2 mutant disease TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable … [Read more…]

Silence Therapeutics Announces Pricing of Underwritten Offering

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc (Nasdaq: SLN) (“Silence”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares (“ADSs”), each representing three ordinary shares, at a price … [Read more…]

Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements

BRAMPTON, Ontario–(BUSINESS WIRE)–Taro Pharmaceuticals Inc. has initiated a voluntary Type 1 recall to the patient level on six (6) lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements. This recall is being conducted … [Read more…]

U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX #CourtofAppeals–Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic. “We are pleased that the U.S. Court of Appeals has once again ruled in … [Read more…]